We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
FLUZONE HIGH-DOSE QUADRIVALENT (Sanofi-Aventis Australia Pty Ltd)
Product name
FLUZONE HIGH-DOSE QUADRIVALENT
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
113 (255 working days)
Active ingredients
influenza virus haemagglutinin
Registration type
EOI
Indication
FLUZONE HIGH-DOSE QUADRIVALENT (suspension for injection) is now also indicated for active immunisation for the prevention of influenza disease. FLUZONE HIGH-DOSE QUADRIVALENT is now indicated for use in persons 60 years of age and older.